Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CDIO vs FEMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FEMY Captures Overall Composite Edge (52.6 HOLD vs 38.2 SELL), While CDIO Leads 3–1 on Growth & Valuation Pillars

FEMY Overall Winner 6-Pillar Tally: CDIO 3 – 1 FEMY (2 Tie) Matrix Metrics: CDIO 3 – 3 FEMY

As of Nov 16, 2026, Femasys Inc. (FEMY) captures the overall head-to-head institutional edge over Cardio Diagnostics Holdings Inc. (CDIO) on higher Unified Composite conviction (52.6/100 HOLD vs. 38.2/100 SELL) after splitting the core matrix 3–3 (led by Valuation Multiples), while CDIO wins 3–1 across the 6-pillar growth and valuation breakdown. CDIO trades at $1.79 (N/M Forward P/E, -42649.8% operating margin) versus FEMY at $1.28 (N/M Forward P/E, -763.9% operating margin).

  • Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. CDIO 38.2/100 SELL) and 4.01β · 72% Vol risk profile, whereas CDIO leads top-line expansion (+25.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CDIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CDIO vs FEMY
CDIO NASDAQ
Cardio Diagnostics Holdings Inc. Common stock
In Vitro & In Vivo Diagnostic Substances
$1.79
-5.29% 1D
Market Cap $5.6M
TTM Revenue $15,185
Forward P/E N/M
Beta / 30D Vol 1.45β · 57% Vol
Unified Composite Score
38.2 / 100 SELL
Tech 15.0 Fund 37.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.6 · SMA20: $1.74 · SMA50: $1.84
FEMY NASDAQ Head-to-Head Winner
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (CDIO 3 – 1 FEMY)

Columns: Metric · CDIO · FEMY
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 4.9x
2. Growth & Scale CDIO
Revenue Growth (YoY) +25.7% -18.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $15,185 $2.3M
Market Cap $5.6M $11.9M
3. Profitability & Quality CDIO
Gross Margin 100.0% 60.9%
Operating Margin -42649.8% -763.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.5% -425.0%
4. Balance Sheet & Cash Flow CDIO
Cash Generation (TTM) -$6.3M -$19M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.5M Net Cash -$658,045 Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CDIO (3) vs FEMY (3)
Institutional Metric CDIO FEMY Criterion Row Edge
Market Capitalization
Scale
$5.6M $11.9M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+25.7% -18.9% Higher Growth CDIO
Operating Margin (TTM)
Profitability
-42649.8% -763.9% Higher Margin FEMY
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.5% -425.0% Higher ROE CDIO
52-Week Range Position
Momentum
12% ($1–$8) 17% ($0–$6) Stronger Trend FEMY
Beta / 30D Volatility
Risk Regime
1.45β · 57% Vol 4.01β · 72% Vol Lower Realized Risk CDIO
Unified Institutional Score
Composite Signal
38.2 / 100 (SELL) 52.6 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$15,185 $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 60.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.3M ($6.5M Net Cash) -$19M (-$658,045 Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CDIO +28.34 pp
CDIO: +5.92% · FEMY: -22.42%
3M Horizon CDIO +35.54 pp
CDIO: -6.28% · FEMY: -41.82%
6M Horizon FEMY +224.03 pp
CDIO: +28.78% · FEMY: +252.81%
1Y Horizon FEMY +102.13 pp
CDIO: -47.35% · FEMY: +54.78%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CDIO Revenue FEMY Revenue CDIO Op. Margin FEMY Op. Margin Margin Leader
FY2020 N/A $0M N/A -668.0% FEMY
FY2021 $0M $0M -68862.2% -706.7% FEMY
FY2022 $0M $0M -478784.3% -961.7% FEMY
FY2023 $0M $0M -42440.4% -1353.4% FEMY
FY2024 $0M $0M -23977.9% -1091.8% FEMY
FY2025 $0M $0M -43737.5% -767.0% FEMY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CDIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CDIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.6M market capitalization and -42649.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CDIO vs FEMY Key Questions & Quantitative Answers

As of Nov 16, 2026, Femasys Inc. (FEMY) captures the overall head-to-head institutional edge over Cardio Diagnostics Holdings Inc. (CDIO) on higher Unified Composite conviction (52.6/100 HOLD vs. 38.2/100 SELL) after splitting the core matrix 3–3 (led by Valuation Multiples), while CDIO wins 3–1 across the 6-pillar growth and valuation breakdown. CDIO trades at $1.79 (N/M Forward P/E, -42649.8% operating margin) versus FEMY at $1.28 (N/M Forward P/E, -763.9% operating margin). Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. CDIO 38.2/100 SELL) and 4.01β · 72% Vol risk profile, whereas CDIO leads top-line expansion (+25.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CDIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 50.6); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDIO leads the Growth & Scale pillar: CDIO posts +25.7% YoY revenue growth and +0.0% YoY earnings growth on $15,185 TTM revenue (100.0% gross margin, -42649.8% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), CDIO cumulative revenue shifted N/A while FEMY shifted N/A. In operating R&D and SG&A reinvestment, CDIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.

FEMY screens cheaper on headline valuation multiples. CDIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CDIO (-93.5% ROE) versus FEMY (-425.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CDIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.45β · 57% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.